Timberlyne Therapeutics Revenue

Biotechnology Research • United States • 11-20 Employees

Timberlyne Therapeutics revenue & valuation

Annual revenue	$1,026,660
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$3,300,000
Total funding	$180,000,000

Key Contacts at Timberlyne Therapeutics

Siyu Shi

Co-Founder, Senior Director Of Operations

Daniel Curran

Chief Executive Officer

Lei Lei Sengchanthalangsy

Executive Director, Head Of Program And Alliance Management

Adam Ingber

Director Of Business Development

Christian Fougner

Co-Founder, Senior Director Of Business Development

Company overview

Headquarters	United States
Website	timberlyne-tx.com
NAICS	541714
Employees	11-20
Socials

Timberlyne Therapeutics Email Formats

Timberlyne Therapeutics uses 4 email formats. The most common is {first initial}{last name} (e.g., jdoe@timberlyne-tx.com), used 53.8% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@timberlyne-tx.com	53.8%
{first name}{last name}	johndoe@timberlyne-tx.com	23.1%
{f2}{last name}	{f2}doe@timberlyne-tx.com	15.4%
{last name}{last name}	doedoe@timberlyne-tx.com	7.7%

About Timberlyne Therapeutics

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of transformational therapies for autoimmune diseases. We are leveraging the extensive drug development expertise of our team to acquire best-in-class assets against compelling targets, and applying them to disease areas with significant unmet need. Timberlyne’s lead program, CM313, is an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity that targets CD38. By targeting CD38, highly expressed on plasma cells, NK cells, and other immune cells, CM313 can modulate multiple arms of the immune system leading to both rapid and durable responses across a range of autoimmune diseases. CM313 has been tested in numerous disease states including Immune Thrombocytopenia, Systemic Lupus Erythematosus, and relapsed/refractory Multiple Myeloma. Timberlyne plans to develop CM313 across a broad range of autoimmune indications. Launched in 2024, Timberlyne has raised $180 million from leading life sciences investors.

Employees by Management Level

Total employees: 11-20

Seniority

Employees

Entry

C-Suite

Founder/Owner

Employees by Department

Timberlyne Therapeutics has 7 employees across 6 departments.

Departments

Number of employees

Funding Data

Explore Timberlyne Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2025-02-09	4	$180,000,000

Funding Insights

$180,000,000

Total funding amount

$180,000,000

Most recent funding amount

Number of funding rounds

Frequently asked questions

Timberlyne Therapeutics is located in US.

Timberlyne Therapeutics generates an estimated annual revenue of $1,026,660. This revenue figure reflects the company's market position and business performance in its industry.

Timberlyne Therapeutics has an estimated valuation of $3,300,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Timberlyne Therapeutics has approximately 11-20 employees. The company continues to grow its workforce to support its business operations and expansion.

Timberlyne Therapeutics has raised a total of $180,000,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.